# Investigating Cannabinoids for Inflammation and Sickle Cell Disease Pain > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dronabinol-sickle-cell-disease-pain-study-protocol/ > **Published:** 2026-03-26T06:06:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:21-04:00 > **Clinical Summary:** Explore the dronabinol sickle cell disease pain study protocol evaluating cannabinoids for inflammation and pain reduction in a randomized controlled trial. --- CED Clinical Relevance  #99High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic PainThcSickle Cell DiseaseRctInflammation Journal PloS one Study Type Randomized Trial Population Human participants Why This Matters Sickle cell disease patients face inadequate pain management options, with opioids providing limited efficacy and significant risks. This represents the first rigorous randomized controlled trial specifically examining dronabinol for chronic SCD pain, addressing a critical gap in evidence-based alternatives. Clinical Summary This 8-week randomized, double-blind, placebo-controlled trial protocol will evaluate FDA-approved dronabinol (synthetic THC) for [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) in sickle cell disease patients. The study design includes both efficacy measures for pain reduction and safety assessments, while tracking inflammatory biomarkers given THC’s demonstrated anti-inflammatory properties. The protocol addresses the urgent clinical need for opioid alternatives in a population where over half experience [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) inadequately managed by current standard treatments. As a protocol paper, actual clinical outcomes remain pending study completion. Dr. Caplan’s Take “I’ve seen promising anecdotal responses to cannabis in SCD patients, but we’ve desperately needed controlled data to guide evidence-based prescribing. This trial design appears methodologically sound for generating the clinical evidence this vulnerable population deserves.” Clinical Perspective 🧠 Clinicians should await the completed study results before incorporating dronabinol into SCD pain protocols. Patients interested in cannabis-based approaches should discuss individual risk-benefit considerations with their hematologist or pain specialist, particularly regarding potential interactions with existing SCD medications and monitoring requirements. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Investigating%20the%20effects%20of%20cannabinoids%20for%20the%20reduction%20of%20inflammation%20and%20...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41604381/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41604381/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Investigating%20the%20effects%20of%20cannabinoids%20for%20the%20reduction%20of%20inflammation%20and%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41604381/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41604381/](https://pubmed.ncbi.nlm.nih.gov/41604381/) Table of Contents - [FAQ](#FAQ)[What is dronabinol and why is it being studied for sickle cell disease pain?](#What_is_dronabinol_and_why_is_it_being_studied_for_sickle_cell_disease_pain) - [How does THC potentially help with sickle cell disease symptoms?](#How_does_THC_potentially_help_with_sickle_cell_disease_symptoms) - [What type of study design is being used to test dronabinol’s effectiveness?](#What_type_of_study_design_is_being_used_to_test_dronabinol8217s_effectiveness) - [What specific outcomes will this study measure?](#What_specific_outcomes_will_this_study_measure) - [Why is this research important for sickle cell disease patients?](#Why_is_this_research_important_for_sickle_cell_disease_patients) - [Related](#Related) ## FAQ #### What is dronabinol and why is it being studied for sickle cell disease pain? Dronabinol is an FDA-approved synthetic form of tetrahydrocannabinol (THC), the psychoactive component of cannabis. It’s being investigated as an alternative to opioids for chronic sickle cell disease pain because current opioid treatments have limited efficacy and significant limitations. #### How does THC potentially help with sickle cell disease symptoms? THC has demonstrated both pain-relieving and anti-inflammatory properties in research studies. Since inflammation is a key driver of sickle cell disease pain and overall disease severity, THC may address both the pain symptoms and underlying inflammatory processes. #### What type of study design is being used to test dronabinol’s effectiveness? This is an 8-week randomized, double-blind, placebo-controlled trial – considered the gold standard for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). This design ensures that neither patients nor researchers know who receives the active treatment versus placebo, eliminating bias in results. #### What specific outcomes will this study measure? The study will assess both the efficacy and safety of dronabinol for pain management in sickle cell disease patients. Additionally, researchers will track biomarkers of inflammation to understand how THC affects the underlying inflammatory processes that contribute to disease severity. #### Why is this research important for sickle cell disease patients? Over half of people with sickle cell disease experience chronic pain that is challenging to treat with current therapies. This study could provide evidence for a new FDA-approved treatment option that addresses both pain and inflammation, potentially improving quality of life for millions affected by this condition globally. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41604381/”, “about”: “plos one randomized trial investigating effects”, “isPartOf”: “PloS one”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Use Patterns and Perception of Acute Pain During Brief Abstinence](https://cedclinic.com/acute-pain-cannabinoid-withdrawal-sex-dependent-cannabis-study/) Explore sex-dependent associations between circulating cannabinoid levels and acute pain perception during cannabis abstinence. [Read More](https://cedclinic.com/acute-pain-cannabinoid-withdrawal-sex-dependent-cannabis-study/) [Cannabis-Based Interventions Might Help a Little with Neuropathic Pain](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) A study summary discussing the modest benefits of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) relief. [Learn More](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) Review the complexities and risks of combining opioids with [cannabis for pain management](https://cedclinic.com/medical-cannabis-patient-benefits/). [Explore Insights](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).